MAP2K7 and lung carcinoma: Crystal et al. in a patient-derived ALK-rearranged lung cancer cell line post-ceritinib harboring MAP2K1K57N activation mutation of MEK, have shown that the MEK inhibitor selumetinib was a potent hit when combined with ceritinib [176].